[Cardioprotective effect and influence on NOS expression of Montelukast sodium in rats].
OBJECTIVE
To determine the protective effect and influence on NOS expression of Montelukast sodium--a leukotriene antagonist on myocardial necrosis in rats.


METHODS
Myocardial ischemia and necrosis were induced in rats by isoproterenol (2 mg.kg-1, s.c., qd for 2 d). Serum activity of LDH, CK, MDA, NO content in myocardium and scope of myocardial necrosis were measured. nNOS, iNOS and eNOS were investigated by immunohistochemical evaluation.


RESULTS
Decreased serum level of LDH, CK, MDA and attenuated myocardial necrosis area were found in rats pretreated with Montelukast sodium 10 and 30 mg.kg-1. Montelukast sodium 30 mg.kg-1 also enhanced NO content in myocardium. Montelukast sodium activated the eNOS expression and reduced the iNOS expression.


CONCLUSIONS
Montelukast sodium is cardioprotective during myocardial injury in rats by halting the leukotrienes-induced inflammatory response and upregulating the eNOS expression as well as downregulating the iNOS expression. This may represent an approach to the treatment of myocardial ischemia with leukotriene antagonists.
Chen
Shan
S
NO. 2 Affiliated Hospital of Medical College, Zhejiang University, Hangzhou 310009, China. Jinchenshan72@sina.com
Jin
Ge
G
Shan
Jiang
J
Zhang
Mei
M
Men
Qun
Q
Xu
Li
L
D000085:Acetates / Q000494:pharmacology*; D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D003521:Cyclopropanes; D005260:Female; D007545:Isoproterenol; D020024:Leukotriene Antagonists / Q000494:pharmacology; D008297:Male; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000201:enzymology* / Q000473:pathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009336:Necrosis; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013440:Sulfides
D000085:Acetates; D002316:Cardiotonic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C496318:Nos2 protein, rat; C496316:Nos3 protein, rat; D007545:Isoproterenol; C093875:montelukast